253 related articles for article (PubMed ID: 21396519)
21. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
22. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
23. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
24. The evolving role of biologics in the treatment of pediatric psoriasis.
Luu M; Cordoro KM
Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
[TBL] [Abstract][Full Text] [Related]
25. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.
Chu DH; Van Voorhees AS; Rosenbach M
Arch Dermatol; 2011 Oct; 147(10):1228-30. PubMed ID: 22006150
[No Abstract] [Full Text] [Related]
26. [1/2 The anti-TNF alpha drugs].
Medjoub M; Limat S; Woronoff-Lemsi MC
Soins; 2007 Oct; (719):59-61. PubMed ID: 18020248
[No Abstract] [Full Text] [Related]
27. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
28. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
[TBL] [Abstract][Full Text] [Related]
29. Erythroderma in the era of biological therapies.
Zattra E; Belloni Fortina A; Peserico A; Alaibac M
Eur J Dermatol; 2012; 22(2):167-71. PubMed ID: 22321651
[TBL] [Abstract][Full Text] [Related]
30. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous pseudolymphoma caused by tumor necrosis factor-α inhibitors was not induced by ustekinumab.
Imafuku S; Tatsukawa R; Ito K; Nakayama J
J Dermatol; 2012 Dec; 39(12):1070. PubMed ID: 22698067
[No Abstract] [Full Text] [Related]
32. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
Gabriel SE
Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
[No Abstract] [Full Text] [Related]
33. Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
[No Abstract] [Full Text] [Related]
34. [Tolerance of biological agents in children].
Bader-Meunier B
Arch Pediatr; 2010 Jun; 17(6):962-3. PubMed ID: 20654981
[No Abstract] [Full Text] [Related]
35. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
Sadlier M; Lally A; Kirby B
Br J Dermatol; 2012 Oct; 167(4):937-8. PubMed ID: 22428935
[No Abstract] [Full Text] [Related]
36. TNF-alpha inhibitors in dermatology.
Cordoro KM; Feldman SR
Skin Therapy Lett; 2007 Sep; 12(7):4-6. PubMed ID: 17940711
[TBL] [Abstract][Full Text] [Related]
37. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
38. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
[No Abstract] [Full Text] [Related]
39. [Psoriasis updates].
Boulinguez S
Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
[No Abstract] [Full Text] [Related]
40. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
Renzo LD; Saraceno R; Schipani C; Rizzo M; Bianchi A; Noce A; Esposito M; Tiberti S; Chimenti S; DE Lorenzo A
Dermatol Ther; 2011; 24(4):446-51. PubMed ID: 21910803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]